DK1507556T3 - Calicheamicin derivative-carrier conjugates - Google Patents

Calicheamicin derivative-carrier conjugates Download PDF

Info

Publication number
DK1507556T3
DK1507556T3 DK03724432.4T DK03724432T DK1507556T3 DK 1507556 T3 DK1507556 T3 DK 1507556T3 DK 03724432 T DK03724432 T DK 03724432T DK 1507556 T3 DK1507556 T3 DK 1507556T3
Authority
DK
Denmark
Prior art keywords
seq
antibody
prednisone
cdr
cyclophosphamide
Prior art date
Application number
DK03724432.4T
Other languages
Danish (da)
English (en)
Inventor
Arthur Kunz
Justin Keith Moran
Joseph Thomas Rubino
Neera Jain
Nishith Merchant
John Francis Dijoseph
Nitin Krishnaji Damle
Mark Edward Ruppen
Eugene Joseph Vidunas
John Mclean Simpson
Paul David Robbins
Andrew George Popplewell
Original Assignee
Wyeth Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1507556(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings Llc filed Critical Wyeth Holdings Llc
Application granted granted Critical
Publication of DK1507556T3 publication Critical patent/DK1507556T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
DK03724432.4T 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates DK1507556T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37744002P 2002-05-02 2002-05-02
PCT/US2003/013910 WO2003092623A2 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates

Publications (1)

Publication Number Publication Date
DK1507556T3 true DK1507556T3 (en) 2016-09-12

Family

ID=29401497

Family Applications (3)

Application Number Title Priority Date Filing Date
DK03724432.4T DK1507556T3 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates
DK16180729.2T DK3127553T3 (da) 2002-05-02 2003-05-02 Calicheamicin-derivat-bærerkonjugater
DK11157981.9T DK2371392T3 (en) 2002-05-02 2003-05-02 Calicheamicin derivative / carrier conjugates

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK16180729.2T DK3127553T3 (da) 2002-05-02 2003-05-02 Calicheamicin-derivat-bærerkonjugater
DK11157981.9T DK2371392T3 (en) 2002-05-02 2003-05-02 Calicheamicin derivative / carrier conjugates

Country Status (33)

Country Link
US (6) US8153768B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP2371392B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP5153057B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR101062628B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100482277C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2003231293A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (3) BR122019027966B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2483552A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (3) CR7557A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (4) CY1116634T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK1507556T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP045445A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2545745T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR17C1054I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HUE027590T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL164946A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (3) LT1507556T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00044I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04010792A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300903I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO339730B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ586071A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (2) PH12013501158B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (5) PL224150B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (3) PT3127553T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (3) RU2422157C3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (3) SG187991A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (3) SI1507556T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TWI379693B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA88599C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003092623A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA200409752B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
WO2003092623A2 (en) * 2002-05-02 2003-11-13 Wyeth Holdings Corporation Calicheamicin derivative-carrier conjugates
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
EP1759582B1 (en) * 2004-05-26 2016-11-23 National University Corporation Kagawa University Preservative solution for cells, tissues and organs comprising rare sugar and preservation method with the use of the same
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
RU2007108716A (ru) * 2004-09-10 2008-10-20 Вайет (Us) Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
MX2008002152A (es) 2005-08-16 2008-04-19 Synta Pharmaceuticals Corp Formulacion de bis(tio-hidrazida amida.
WO2007024536A2 (en) 2005-08-24 2007-03-01 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP5806444B2 (ja) * 2005-12-02 2015-11-10 ノバルティス アーゲー 免疫原性組成物で使用するためのナノ粒子
US20070160577A1 (en) * 2005-12-06 2007-07-12 Wyeth Interleukin-11 compositions and methods of use
ES2498517T3 (es) 2006-03-10 2014-09-24 Wyeth Llc Anticuerpos anti-5T4 y usos de los mismos
EP1859811B1 (en) * 2006-05-27 2011-08-24 Faulstich, Heinz, Dr. Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy
TR201807021T4 (tr) 2006-07-13 2018-06-21 Wyeth Llc Geliştirilmiş glikosilasyon şablonuna sahip pıhtılaşma faktörü ıx?un üretilmesi.
MX2009001877A (es) 2006-08-21 2009-03-02 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
AU2007308145A1 (en) * 2006-10-12 2008-04-17 Wyeth Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
ES2678060T3 (es) * 2006-12-01 2018-08-08 E. R. Squibb & Sons, L.L.C. Anticuerpos, en particular, anticuerpos humanos, que se unen a CD22 y usos de los mismos
CA2671900A1 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
MX2009007368A (es) * 2007-01-16 2009-07-16 Wyeth Corp Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1).
PL2115126T3 (pl) * 2007-03-02 2015-08-31 Wyeth Llc Zastosowanie miedzi i glutaminianu w hodowli komórkowej do wytwarzania polipeptydów
MX2009012587A (es) 2007-05-22 2010-05-14 Wyeth Llc Proceso mejorado para la elaboracion de hidrazidas.
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
JP5727786B2 (ja) * 2007-10-19 2015-06-03 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１９結合性物質およびその使用
AU2008342956A1 (en) * 2007-12-21 2009-07-09 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
RU2486203C2 (ru) * 2007-12-26 2013-06-27 Биотест Аг Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления
WO2009080831A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
CA2710471C (en) * 2007-12-26 2018-06-05 Biotest Ag Immunoconjugates targeting cd138 and uses thereof
ES2475201T3 (es) * 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
US20090186026A1 (en) * 2008-01-18 2009-07-23 Wyeth Ephrin and eph receptor agonists for modulation of bone formation and resorption
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
FR2930443B1 (fr) 2008-04-29 2010-06-25 Oreal Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12
PT2281006T (pt) 2008-04-30 2017-12-06 Immunogen Inc Agentes de reticulação e as suas utilizações
RU2765240C2 (ru) * 2009-06-03 2022-01-27 Иммьюноджен, Инк. Способы конъюгации
WO2011098518A2 (en) * 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
US20120222979A1 (en) * 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
KR102272828B1 (ko) 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
MX351991B (es) 2011-10-21 2017-11-03 Pfizer Adicion de hierro para mejorar cultivo celular.
JP6218746B2 (ja) 2011-12-08 2017-10-25 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８を標的とする免疫複合体の使用
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151670A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
SG10201705150RA (en) 2012-12-21 2017-07-28 Bioalliance Cv Hydrophilic self-immolative linkers and conjugates thereof
US11193111B2 (en) 2013-01-17 2021-12-07 Case Western Reserve University Viral nanoparticle multimers
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2992015B1 (en) * 2013-05-02 2018-08-29 F.Hoffmann-La Roche Ag Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
RU2640197C1 (ru) * 2013-11-04 2017-12-27 Пфайзер Инк. Промежуточные соединения и способы синтеза производных калихеамицина
PE20161413A1 (es) 2013-11-04 2017-01-10 Stemcentrx Inc Conjugados de anticuerpo anti-efna4-farmaco
CN106414465B (zh) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
US10544395B2 (en) 2014-03-19 2020-01-28 Pfizer Inc. Method of cell culture
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
CN106661124A (zh) 2014-06-20 2017-05-10 荷商台医(有限合伙)公司 抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
JP6731405B2 (ja) 2014-11-07 2020-07-29 ケース ウエスタン リザーブ ユニバーシティ ウイルス粒子を用いた癌免疫療法
CN113876962A (zh) 2015-04-07 2022-01-04 纪念斯隆-凯特琳癌症中心 纳米粒子免疫偶联物
KR20170139110A (ko) * 2015-04-21 2017-12-18 애브비 스템센트알엑스 엘엘씨 칼리케아마이신 구성체 및 사용 방법
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017004123A1 (en) 2015-06-29 2017-01-05 Case Western Reserve University Anticancer drug-containing plant virus particles
MX2018000016A (es) 2015-07-02 2019-01-31 Otsuka Pharma Co Ltd Composiciones farmaceuticas liofilizadas.
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. BRIDGE LINKER FOR CONJUGATING CELL BINDING MOLECULES
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3725332B1 (en) * 2015-07-16 2023-10-04 Case Western Reserve University Plant virus particles for delivery of antimitotic agents
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
JP7001585B2 (ja) 2015-09-23 2022-02-04 ファイザー・インク 細胞および細胞培養の方法
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
KR102784576B1 (ko) 2016-01-08 2025-03-21 알트루바이오 인코퍼레이티드 사가 항-psgl-1 항체 및 이들의 용도
US20170281758A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
CN109415688B (zh) 2016-04-05 2022-08-02 辉瑞公司 细胞培养工艺
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
WO2018017985A1 (en) 2016-07-21 2018-01-25 Case Western Reserve University Plant virus or virus-like particle constructs
US11654117B2 (en) 2016-11-03 2023-05-23 Case Western Reserve University Melt processed viral nanoparticle constructs
NZ752394A (en) 2016-11-14 2021-07-30 Hangzhou Dac Biotech Co Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US11590183B2 (en) 2017-03-10 2023-02-28 Case Western Reserve University Cancer immunotherapy using virus particles
EP3596206A1 (en) 2017-03-16 2020-01-22 Pfizer Inc Tyrosine prototrophy
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
US11672840B2 (en) 2017-05-17 2023-06-13 Case Western Reserve University Anticancer trail-targeted plant virus particles
CA3071755A1 (en) 2017-08-03 2019-02-07 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
EP3681989A1 (en) 2017-09-15 2020-07-22 Bristol-Myers Squibb Company Online biomass capacitance monitoring during large scale production of polypeptides of interest
CN111630070B (zh) 2017-10-13 2024-07-30 哈普恩治疗公司 三特异性蛋白质及使用方法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019084555A1 (en) 2017-10-27 2019-05-02 Case Western Reserve University TYMOVIRUS VIRUSES AND VIRAL TYPE PARTICLES USEFUL AS NANOVECTORS FOR IMAGING AND THERAPEUTIC AGENTS
WO2019178489A1 (en) 2018-03-16 2019-09-19 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
RS61770B1 (sr) 2018-05-30 2021-05-31 Abbvie Stemcentrx Llc Konjugati anti-sez6 antitela i leka i metodi primene
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
MX2021003554A (es) 2018-09-25 2021-05-27 Harpoon Therapeutics Inc Proteinas de union a dll3 y metodos de uso.
AU2019385497A1 (en) 2018-11-20 2021-06-17 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
CA3121884A1 (en) 2018-12-06 2020-06-11 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
WO2020168090A1 (en) * 2019-02-13 2020-08-20 Geerlings Maurits W Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies
WO2020187998A1 (en) 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
AU2020310892A1 (en) * 2019-07-08 2022-03-03 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US11896676B2 (en) 2019-08-07 2024-02-13 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
EP4069312A4 (en) * 2019-12-04 2024-03-27 The Research Foundation for the State University of New York COMPOSITIONS AND METHODS FOR REDUCING OFF-TARGET TOXICITY OF ANTIBODY-DRUG CONJUGATES
US11529430B2 (en) 2019-12-20 2022-12-20 Case Western Reserve University Polydopamine decorated tobacco mosaic theranostic virus nanoparticles
US12203073B2 (en) 2019-12-20 2025-01-21 Case Western Reserve University Plant viral RNA delivery nanoparticles and uses thereof
US20250262293A1 (en) 2020-07-07 2025-08-21 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
EP4473096A1 (en) 2022-02-02 2024-12-11 Pfizer Inc. Cysteine prototrophy
EP4588491A1 (en) * 2022-09-16 2025-07-23 National Institutes for Quantum Science and Technology Production method of intermediate for radiopharmaceutical composition, and purification kit for intermediate for radiopharmaceutical composition
AU2023370106A1 (en) 2022-10-25 2025-05-08 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy for the treatment of cancer
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
WO2024251846A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with mek inhibitors for the treatment of cancer
WO2024251854A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
WO2025063789A1 (ko) * 2023-09-21 2025-03-27 주식회사 피노바이오 운반체-약물 접합체 및 dnmt-1 저해제의 병용 요법
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133528T2 (de) 1990-06-27 2006-09-07 Princeton University Proteinkomplex p53/p90
SK281143B6 (sk) * 1991-03-06 2000-12-11 Merck Patent Gesellschaft Mit Beschr�Nkter Haftung Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5712474A (en) * 1993-09-29 1998-01-27 Canon Kabushiki Kaisha Image processing apparatus for correcting blurring of an image photographed by a video camera
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ATE306930T1 (de) * 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
MX9701075A (es) 1994-08-12 1998-03-31 Myriad Genetics Inc Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ATE383430T1 (de) 1997-03-20 2008-01-15 Us Gov Health & Human Serv Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DK0999853T3 (da) * 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US6183477B1 (en) * 1998-09-04 2001-02-06 Smith & Nephew, Inc. Attachment tool for drill guide
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
JP2000226336A (ja) * 1998-11-30 2000-08-15 Sankyo Co Ltd 免疫グロブリン製剤
CA2351346C (en) 1998-12-10 2015-09-01 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
PT1194167E (pt) * 1999-06-09 2009-10-23 Immunomedics Inc Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b
AU6558400A (en) * 1999-08-17 2001-03-13 Novo Nordisk A/S Stabilisation of freeze-dried cake
ES2194782T5 (es) * 1999-10-12 2014-08-20 Oxoid (Ely) Limited Procedimiento mejorado de detección de bacterias acidorresistentes del género Helicobacter en las heces
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
WO2003092623A2 (en) * 2002-05-02 2003-11-13 Wyeth Holdings Corporation Calicheamicin derivative-carrier conjugates

Also Published As

Publication number Publication date
RU2422157C3 (ru) 2021-04-23
RU2016141576A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-05-03
US8747857B2 (en) 2014-06-10
PL413302A1 (pl) 2016-05-23
CR20130390A (es) 2013-11-08
ZA200409752B (en) 2010-08-25
RU2004135101A (ru) 2005-06-27
HUE030806T2 (hu) 2017-05-29
PT3127553T (pt) 2022-01-24
US8153768B2 (en) 2012-04-10
ES2593304T3 (es) 2016-12-07
SI3127553T1 (sl) 2022-02-28
JP2005524700A (ja) 2005-08-18
EP3127553A1 (en) 2017-02-08
NO339730B1 (no) 2017-01-23
KR101062628B1 (ko) 2011-09-07
PT2371392E (pt) 2015-10-07
PL224844B1 (pl) 2017-02-28
PH12013501159A1 (en) 2015-12-02
HK1162926A1 (en) 2012-09-07
ES2545745T3 (es) 2015-09-15
CA2871117A1 (en) 2003-11-13
CR20120364A (es) 2012-10-05
PH12013501158A1 (en) 2015-11-09
JP5441971B2 (ja) 2014-03-12
LTC2371392I2 (lt) 2019-03-25
PL228741B1 (pl) 2018-05-30
RU2678818C2 (ru) 2019-02-04
LUC00044I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-02-26
EP1507556B1 (en) 2016-07-27
RU2602878C2 (ru) 2016-11-20
DK3127553T3 (da) 2022-01-31
EP1507556A4 (en) 2009-01-07
CR7557A (es) 2008-10-03
RU2422157C2 (ru) 2011-06-27
IL230659A (en) 2016-02-29
WO2003092623A3 (en) 2004-03-18
EP3127553B1 (en) 2021-12-01
KR101125524B1 (ko) 2012-03-22
SI2371392T1 (sl) 2015-10-30
CN100482277C (zh) 2009-04-29
ECSP045445A (es) 2005-01-28
TW200404005A (en) 2004-03-16
CY2017035I1 (el) 2018-04-04
JP2012051900A (ja) 2012-03-15
NO20161431A1 (no) 2005-01-25
NO344509B1 (no) 2020-01-20
SG10201700289RA (en) 2017-02-27
PT1507556T (pt) 2016-09-28
NO20044663L (no) 2005-01-25
FR17C1054I2 (fr) 2019-01-11
BR0309868A (pt) 2005-10-18
RU2602878C3 (ru) 2021-11-24
WO2003092623A2 (en) 2003-11-13
SG165158A1 (en) 2010-10-28
SI1507556T1 (sl) 2016-10-28
TW201231089A (en) 2012-08-01
CY2017035I2 (el) 2018-04-04
ZA201003874B (en) 2019-12-18
HK1070825A1 (en) 2005-06-30
JP5153057B2 (ja) 2013-02-27
PL224150B1 (pl) 2016-11-30
NZ573563A (en) 2010-10-29
PL410219A1 (pl) 2015-03-30
HUE027590T2 (hu) 2016-11-28
PH12013501159B1 (en) 2015-12-02
PL410218A1 (pl) 2015-03-30
US20040192900A1 (en) 2004-09-30
IL230659A0 (en) 2014-03-31
PL224001B1 (pl) 2016-11-30
LT3127553T (lt) 2022-04-11
CN1665532A (zh) 2005-09-07
BRPI0309868B1 (pt) 2020-04-28
EP2371392B1 (en) 2015-07-08
US9351986B2 (en) 2016-05-31
BR122019027966B8 (pt) 2021-07-27
US8835611B2 (en) 2014-09-16
SG187991A1 (en) 2013-03-28
IL164946A0 (en) 2005-12-18
JP2013163678A (ja) 2013-08-22
MXPA04010792A (es) 2005-03-07
US20040082764A1 (en) 2004-04-29
US20120213804A1 (en) 2012-08-23
EP1507556A2 (en) 2005-02-23
HUS1700038I1 (hu) 2017-11-28
CY1116634T1 (el) 2017-03-15
LT1507556T (lt) 2016-10-10
LTPA2017036I1 (lt) 2017-11-27
JP5756489B2 (ja) 2015-07-29
PL374523A1 (en) 2005-10-31
TWI379693B (en) 2012-12-21
AU2009202609B2 (en) 2012-07-26
IL164946A (en) 2015-06-30
NO2017061I1 (no) 2017-11-21
HUE057124T2 (hu) 2022-04-28
RU2011108928A (ru) 2012-09-20
US20140235835A1 (en) 2014-08-21
BRPI0309868B8 (pt) 2021-05-25
KR20050006220A (ko) 2005-01-15
PL222725B1 (pl) 2016-08-31
ES2916174T3 (es) 2022-06-28
US20180339058A1 (en) 2018-11-29
DK2371392T3 (en) 2015-08-31
RU2016141576A (ru) 2018-05-03
EP2371392A1 (en) 2011-10-05
AU2009202609A1 (en) 2009-07-16
BR122019027966B1 (pt) 2020-11-17
CY1117973T1 (el) 2017-05-17
AU2003231293A1 (en) 2003-11-17
HUE057124T4 (hu) 2022-02-28
JP2015061875A (ja) 2015-04-02
LUC00044I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-11-03
JP6872376B2 (ja) 2021-05-19
NZ586071A (en) 2012-02-24
CY1124900T1 (el) 2023-01-05
FR17C1054I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-01-12
BR122019027974B1 (pt) 2022-06-14
CA2483552A1 (en) 2003-11-13
PH12013501158B1 (en) 2015-11-09
TWI438010B (zh) 2014-05-21
US20160303252A1 (en) 2016-10-20
PL411824A1 (pl) 2015-08-17
NL300903I2 (nl) 2018-02-08
JP2017105801A (ja) 2017-06-15
KR20110050753A (ko) 2011-05-16
BE2017C049I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-08-09
UA88599C2 (ru) 2009-11-10

Similar Documents

Publication Publication Date Title
DK1507556T3 (en) Calicheamicin derivative-carrier conjugates
AU2017204487B2 (en) Calicheamicin derivative-carrier conjugates
AU2012244218C1 (en) Calicheamicin derivative-carrier conjugates
HK1233519A1 (en) Calicheamicin derivative-carrier conjugates
HK1233519A (en) Calicheamicin derivative-carrier conjugates
HK1233519B (en) Calicheamicin derivative-carrier conjugates
HK1070825B (en) Calicheamicin derivative-carrier conjugates
HK1162926B (en) Calicheamicin derivative-carrier conjugates